Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
| | | | |

Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome

On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…

Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
| | | |

Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound

On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…

ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials
| | | |

ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials

On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib,…